FBTIX — Fidelity Advisor Biotechnology Fund
Data updated: 2026-06-26
FBTIX — Fidelity Advisor Biotechnology Fund. United States Multi-Cap / All-Cap Growth Health Care Equity. Holdings, fees, performance and SEC filings.
FBTIX Fund Overview
FBTIX — Fidelity Advisor Biotechnology Fund is a US mutual fund managed by Fidelity Advisor Series VII, categorised as United States Multi-Cap / All-Cap Growth Health Care Equity. ABC INVEST provides holdings, performance, costs, cashflows, risk data, prospectus documents and SEC filings, sourced from SEC filings.
- Type: US mutual fund
- Manager: Fidelity Advisor Series VII
- Category: United States Multi-Cap / All-Cap Growth Health Care Equity
- Assets under management: $1.90B
- 1-year return: 52.6%
- Ticker: FBTIX
- SEC CIK: 0000315700
- SEC series ID: S000005321
- Share class ID: C000014523
FBTIX Holdings
Top 10 holdings of Fidelity Advisor Biotechnology Fund by percentage of net assets, from the fund's latest SEC N-PORT filing.
| Holding | % of net assets |
|---|---|
| Abbvie, Inc. | 14.83% |
| Alnylam Pharmaceuticals, Inc. | 5.52% |
| Gilead Sciences, Inc. | 5.42% |
| Insmed, Inc. | 3.51% |
| Cogent Biosciences, Inc. | 3.45% |
| Dianthus Therapeutics, Inc. | 3.37% |
| Spyre Therapeutics, Inc. | 3.33% |
| Ascendis Pharma A/s | 3.24% |
| Argenx SE | 3.17% |
| Biogen, Inc. | 2.92% |
FBTIX Portfolio Allocation
Asset-class allocation of Fidelity Advisor Biotechnology Fund by percentage of net assets, from the latest SEC N-PORT filing.
| Asset class | Allocation |
|---|---|
| Equity | 99.2% |
| Cash & Equivalents | 3.3% |
| Fixed Income | 0.1% |
FBTIX Performance
Total returns for FBTIX (as of 2026-09-01), from SEC filings.
| Period | Total return |
|---|---|
| YTD | 4.4% |
| 1 year | 52.6% |
| 3 years (annualised) | 20.3% |
| 5 years (annualised) | 9.3% |
FBTIX Risk Information
Risk metrics for FBTIX, derived from monthly returns in SEC filings.
- 1-year volatility (annualised): 18.1%
FBTIX Costs and Fees
FBTIX costs about $71 per $10,000 invested per year in fund expenses.
- Net expense ratio: 0.71%
- Gross expense ratio: 0.71%
- Portfolio turnover: 51%
- Brokerage commissions: 3.94 bps of average net assets (SEC N-CEN)
FBTIX Cashflows
Over the 12 months to 2026-04, Fidelity Advisor Biotechnology Fund had net outflows of $97.44M, from monthly SEC N-PORT filings.
| Month | Net flow |
|---|---|
| 2026-04 | −$7.05M |
| 2026-03 | −$5.78M |
| 2026-02 | −$3.95M |
| 2026-01 | −$3.40M |
| 2025-12 | $25.80M |
| 2025-11 | $6.52M |
FBTIX Debt Constituents
Largest debt holdings of Fidelity Advisor Biotechnology Fund by percentage of net assets, from the latest SEC N-PORT filing.
| Debt holding | % of net assets |
|---|---|
| Wugen, Inc. | 0.05% |
| Kartos Therapeutics, Inc. | 0.01% |
FBTIX Prospectus and SEC Filings
Official Fidelity Advisor Biotechnology Fund filings on SEC EDGAR — prospectus, portfolio holdings and annual reports.
- Prospectus (485BPOS) — filed 2025-09-24
- Prospectus (485BPOS) — filed 2024-09-24
- Prospectus supplement (497) — filed 2024-03-01
- Portfolio holdings (N-PORT) — filed 2026-06-26
- Portfolio holdings (N-PORT) — filed 2026-03-25
- Portfolio holdings (N-PORT) — filed 2025-12-23
- Annual census (N-CEN) — filed 2025-10-14
- Annual census (N-CEN) — filed 2024-10-15
Related Funds
Other United States Multi-Cap / All-Cap Growth Health Care Equity funds tracked on ABC INVEST:
Data Sources
ABC INVEST compiles this page from public filings made to the U.S. Securities and Exchange Commission (SEC) through EDGAR: portfolio holdings and monthly cashflows from Form N-PORT, expenses and returns from fund prospectuses (Form 485BPOS) and the SEC DERA Risk/Return Summary data sets, annual data from Form N-CEN, and shareholder reports from Form N-CSR.